GlassScriptPhysician profile
Olivera Chandler
NPI 1629230842
$2,651.63
in general payments reported to CMS, 2019-2025
14 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $29.99 · 2021: $37.07 · 2022: $580 · 2023: $581 · 2024: $642 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $789.41 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $601.34 | 2021-2025 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $317.73 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $275.47 | 2019-2025 | |
| Scpharmaceuticals INC. | $174.92 | 2025 | |
| Janssen Pharmaceuticals, INC | $131.52 | 2022-2024 | Xarelto |
| Abbott Laboratories | $119.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.89 | 2022-2025 | Lokelma, Farxiga, Brilinta |
| Atricure, INC. | $59.00 | 2022 | |
| Medtronic, INC. | $40.00 | 2023 | Onyx Frontier |
| Lexicon Pharmaceuticals, INC. | $20.40 | 2023 | Inpefa |
| Boston Scientific Corporation | $16.03 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.88 | 2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivera Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.